A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)

Trial Profile

A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs ACT 1 (Primary)
  • Indications Diabetic foot ulcer; Leg ulcer; Scars
  • Focus Registrational; Therapeutic Use
  • Acronyms GAIT 1
  • Sponsors FirstString Research
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 06 Feb 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
    • 27 Jul 2016 According to Relief Therapeutics media release, top-line data is expected in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top